Changes in platelet counts after lusutrombopag therapy and prior to the invasive procedures.

<p>(A) Patients with baseline platelet count ≤30,000/μL. (B) Patients with baseline platelet count >30,000/μL. (C) Patients with baseline platelet count ≤30,000/μL. Platelet counts in patients with a baseline platelet count ≤30,000/μL were 24±5.9 at baseline which increased to 24±5.9, 28±7.8, 35±8.3, 39±9.8, 43±1.2, and 52±1.6 ×10<sup>3</sup>/μL at 3, 5, 7, 9, 11, and 13 days after administration, respectively. *: p<0.05. (D) Patients with baseline platelet count >30,000/μL. Platelet counts in patients with a baseline platelet count >30,000/μL were 43±8.0 at baseline which increased to 50±1.4, 57±2.1, 64±2.2, 74±2.2, 81±2.5, and 82±2.7 ×10<sup>3</sup>/μL at 3, 5, 7, 9, 11, and 13 days after administration, respectively. *: p<0.05.</p>